C-Reactive Protein as a Predictor of Cardiovascular Events and Mortality in Obstructive Sleep Apnea: A Propensity-Matched Analysis Using the TriNetX Research Network.
Ekow Essien, Abena Agyekum, Abraham Carboo, Gloria Amoako, Justice Owusu-Achiaw, Samuel B Governor
{"title":"C-Reactive Protein as a Predictor of Cardiovascular Events and Mortality in Obstructive Sleep Apnea: A Propensity-Matched Analysis Using the TriNetX Research Network.","authors":"Ekow Essien, Abena Agyekum, Abraham Carboo, Gloria Amoako, Justice Owusu-Achiaw, Samuel B Governor","doi":"10.1055/s-0046-1829074","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Obstructive sleep apnea (OSA) increases cardiovascular disease risk through systemic inflammation, particularly through elevated C-reactive protein (CRP). This study investigated whether CRP stratification predicts mortality and cardiovascular events in OSA patients.</p><p><strong>Methods: </strong>We conducted a retrospective cohort analysis using the TriNetX Research Network, encompassing electronic health records from 130 healthcare institutions. Adults (ages 18-90 years) with OSA were stratified by CRP concentration: elevated (≥ 3.0 mg/L) versus low (≤ 2.9 mg/L). After propensity score matching for demographics and comorbidities, 240,727 participants per cohort were followed for five years. Primary outcome was all-cause mortality; secondary outcomes included cardiovascular events, arrhythmias, and acute kidney injury.</p><p><strong>Results: </strong>Elevated CRP was associated with significantly higher all-cause mortality (11.3% versus 7.0%; HR 1.695, 95% CI 1.662-1.727; <i>p</i> < 0.001). The elevated CRP group demonstrated heightened cardiovascular risk: cardiogenic shock (1.0% versus 0.5%; HR 2.003), heart failure (9.8% versus 6.5%; HR 1.594), pulmonary hypertension (4.9% versus 3.4%; HR 1.508), and acute kidney injury (11.0% versus 6.4%; HR 1.825), all <i>p</i> < 0.001. Arrhythmic complications were also increased: atrial fibrillation/flutter (6.3% versus 4.8%; HR 1.372) and ventricular tachycardia (2.3% versus 1.8%; HR 1.388), both <i>p</i> < 0.001.</p><p><strong>Conclusion: </strong>Elevated CRP constitutes a robust predictor of mortality and cardiovascular morbidity in OSA populations. Assessment of inflammatory biomarkers may enhance risk stratification, informing intensified monitoring and targeted therapeutic interventions.</p>","PeriodicalId":21848,"journal":{"name":"Sleep Science","volume":"19 2","pages":"1-9"},"PeriodicalIF":1.6000,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13652664/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sleep Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0046-1829074","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Obstructive sleep apnea (OSA) increases cardiovascular disease risk through systemic inflammation, particularly through elevated C-reactive protein (CRP). This study investigated whether CRP stratification predicts mortality and cardiovascular events in OSA patients.
Methods: We conducted a retrospective cohort analysis using the TriNetX Research Network, encompassing electronic health records from 130 healthcare institutions. Adults (ages 18-90 years) with OSA were stratified by CRP concentration: elevated (≥ 3.0 mg/L) versus low (≤ 2.9 mg/L). After propensity score matching for demographics and comorbidities, 240,727 participants per cohort were followed for five years. Primary outcome was all-cause mortality; secondary outcomes included cardiovascular events, arrhythmias, and acute kidney injury.
Results: Elevated CRP was associated with significantly higher all-cause mortality (11.3% versus 7.0%; HR 1.695, 95% CI 1.662-1.727; p < 0.001). The elevated CRP group demonstrated heightened cardiovascular risk: cardiogenic shock (1.0% versus 0.5%; HR 2.003), heart failure (9.8% versus 6.5%; HR 1.594), pulmonary hypertension (4.9% versus 3.4%; HR 1.508), and acute kidney injury (11.0% versus 6.4%; HR 1.825), all p < 0.001. Arrhythmic complications were also increased: atrial fibrillation/flutter (6.3% versus 4.8%; HR 1.372) and ventricular tachycardia (2.3% versus 1.8%; HR 1.388), both p < 0.001.
Conclusion: Elevated CRP constitutes a robust predictor of mortality and cardiovascular morbidity in OSA populations. Assessment of inflammatory biomarkers may enhance risk stratification, informing intensified monitoring and targeted therapeutic interventions.